XT
BRNS

XTX Topco’s Barinthus Biotherapeutics BRNS Stock Holding History

XTX Topco’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.78K Buy
+14,819
New +$9.66K ﹤0.01% 4029
2025
Q4 		– Sell
-13,007
Closed -$16.3K – 3344
2025
Q3 		$16.3K Buy
+13,007
New +$16.3K ﹤0.01% 2365

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

XTX Topco's BRNS Position: Q2 2026 in Review

XTX Topco opened a new position in Barinthus Biotherapeutics (BRNS) in Q2 2026: 14,819 shares worth $9.78K. The stake represents ﹤0.01% of the portfolio and ranks #4029 among its holdings. This is a return to the name: XTX Topco previously reported a position in BRNS as recently as Q3 2025.

XTX Topco first reported a position in BRNS in Q3 2025 and has held it in 2 quarters since. The position peaked at $16.3K in Q3 2025. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • XTX Topco held 14,819 shares of Barinthus Biotherapeutics worth $9.78K as of Q2 2026.
  • Barinthus Biotherapeutics was a new XTX Topco position in Q2 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #4029 holding.
  • XTX Topco first reported a position in Barinthus Biotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • XTX Topco's Barinthus Biotherapeutics position peaked at $16.3K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.